bursa escort ankara escort adana escort manavgat escort eskişehir escort malatya escort diyarbakır escort urfa escort şişli escort avcılar escort sarıyer escort şişli escort mecidiyeköy escort beşiktaş escort pendik escort maltepe escort ataşehir escort kadıköy escort çeşme escort konya escort beylikdüzü escort esenyurt escort ankara escort mezitli escort manavgat escort konya escort antalya escort diyarbakır escort esenyurt escort

Japan’s Astellas to buy Audentes for $3 billion to boost gene therapy division

JAPAN – Astellas Pharma Inc, Japan’s second largest drugmaker by sales has agreed to buy Audentes Therapeutics Inc for about US$3 billion in cash as it seeks to make genetic medicines a key area of growth.

Gene therapies are one of the hottest areas of drug research and Astellas, is offering US$60 per share for San Francisco-based Audentes, a 110% premium to its price in December 2019.

Citi analyst Hidemaru Yamaguchi said that while the deal looked expensive, it was a positive move for Astellas as Audentes had “cutting-edge gene therapy modalities”.

“We thought it was only a matter of time before Astellas entered the gene therapy market, given its licensing of development rights for a domestic gene therapy,” he wrote in a note for clients.

Gene therapies aim to cure diseases by replacing the missing or mutated version of a gene found in a patient’s cells with healthy copies.

With the potential to cure devastating illnesses in a single dose, drugmakers say they justify prices well above US$1 million per patient.

Audentes’ investigational drug, AT132, is being developed to treat a rare genetic neuromuscular disorder, which results in extreme muscle weakness, respiratory failure and in some cases early death.

“Audentes has developed a robust pipeline of promising product candidates which are complementary to our existing pipeline, including its lead program AT132,” Astellas Chief Executive Kenji Yasukawa said in a news release.

The all-cash deal is expected to close in the first quarter of 2020 and is subject to regulatory approval including U.S. antitrust clearance.

Austellas plans to seek FDA approval in mid-2020 for the AT312 drug which has shown promising results in the treatment of X-linked myotubular myopathy (XLMTM) seen mainly in male infants.

Only about 40 boys are born in the U.S. with the condition each year, so that would yield just $80 million in revenue, wrote Jefferies analyst Stephen Barker, assuming a maximum price tag for the treatment.

“The US$3 billion acquisition price is therefore more likely to be mainly predicated on the firm’s technology platform and manufacturing capabilities,” Barker wrote.

Shares in Astellas fell 1.3% on Tuesday in Tokyo, underperforming a 0.6% decline in the broader market N225.

Astellas Pharma Inc. was formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd and Fujisawa Pharmaceutical Co., Ltd.

Headquartered are in Tokyo, Astella employs about 17,000 people and is a member of the Mitsubishi UFJ Financial Group.

Astellas’ franchise areas are urology, immunology (transplantation), cardiology, and infectious disease.

It also has priority areas for R&D are infectious diseases, diabetes, gastrointestinal diseases, oncology, and diseases of the central nervous system.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.